BECLATE ROTACAPS 100 MCG

Beclate Rotacaps 100 MCG is a corticosteroid that is effective in relieving symptoms associated with asthma and allergic rhinitis. The topical form of this medication is used in the treatment of a variety of skin conditions such as psoriasis, eczema, and dermatitis. This medicine usually is not recommended for the primary treatment for asthma and for use in patients below 5 years of age. We at Online Blue Pills are instrumental in providing Beclate Rotacaps 100 MCG for valued customers. Apart from this, we promise to make the scheduled delivery of this medicine for our patrons. Our offered medicine is widely appreciated by our clients and is available at the most affordable price. Log on to our website to buy Beclate Rotacaps 100 MCG online.

BECLATE ROTACAPS 100 MCG Qualitative and Quantitative Composition

BECLATE-100 Rotacaps

Each capsule contains:

Beclomethasone Dipropionate IP....... 100 mcg

BECLATE-200 Rotacaps

Each capsule contains:

Beclomethasone Dipropionate IP....... 200 mcg

BECLATE-400 Rotacaps

Each capsule contains:

Beclomethasone Dipropionate IP....... 400 mcg

Adults

Prophylactic management in:-

Mild asthma (PEF values greater than 80% predicted at baseline with less than 20% variability):

Patients requiring intermittent symptomatic bronchodilator asthma medication on more than an occasional basis

Moderate asthma (PEF values 60 - 80% predicted at baseline with 20 - 30% variability):

Patients requiring regular asthma medication and patients with unstable or worsening asthma on other prophylactic therapy or bronchodilator alone

Severe asthma (PEF values less than 60% predicted at baseline with greater than 30% variability):

Patients with severe chronic asthma

Children

Any child who requires prophylactic asthma medication.

Special Warnings & Precautions for Use

The management of asthma should follow a stepwise program, and patient response should be monitored clinically and by lung function tests.

Increasing use of short-acting inhaled beta2-agonists to control symptoms indicates deterioration of asthma control. Under these conditions, the patient's therapy plan should be reassessed.

Sudden and progressive deterioration in asthma control is potentially life-threatening and consideration should be given to increasing corticosteroid dosage. In patients considered at risk, daily flow monitoring may be instituted.

BECLATE Rotacaps is not for use in acute attacks but for routine long-term management. Patients will require a fast- and short-acting inhaled bronchodilator to relieve acute asthmatic symptoms.

Patients' inhalation technique should be checked to make sure that aerosol actuation is synchronized with inspiration of breath for optimum delivery of the drug to the lungs. Lack of response or severe exacerbations of asthma should be treated by increasing the dose of inhaled beclomethasone dipropionate and, if necessary, by giving a systemic steroid and/or an antibiotic if there is an infection.

Systemic effects may occur with any inhaled corticosteroid, particularly at high doses prescribed for long periods; these effects are much less likely to occur than with oral corticosteroids. Possible systemic effects include Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma and more rarely a range of psychological or behavourial effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children). It is important, therefore, that the dose of inhaled corticosteroid is titrated to the lowest dose at which effective control is maintained.

It is recommended that the height of children receiving prolonged treatment with inhaled corticosteroid is regularly monitored.

Certain individuals can show greater susceptibility to the effects of inhaled corticosteroid than do most patients.

Because of the possibility of impaired adrenal response, patients transferring from oral steroid therapy to inhaled beclomethasone dipropionate therapy should be treated with special care, and adrenocortical function regularly monitored.

Following introduction of inhaled beclomethasone dipropionate, withdrawal of systemic therapy should be gradual and patients encouraged to carry a steroid warning card indicating the possible need for additional therapy in times of stress.

Similarly replacement of systemic steroid treatment with inhaled therapy sometimes unmasks allergies such as allergic rhinitis or eczema previously controlled by the systemic drug. These allergies should be symptomatically treated with antihistamine and/or topical preparations, including topical steroids.

Treatment with BECLATE Rotacaps should not be stopped abruptly.

As with all inhaled corticosteroids, special care is necessary in patients with active or quiescent pulmonary tuberculosis.

Special care is necessary in patients with active or quiescent pulmonary tuberculosis.

Visual Disturbance

Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes, which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy which have been reported after use of systemic and topical corticosteroids.